RT Journal Article
SR Electronic
T1 Increased burden of cardiovascular disease in people with liver disease: unequal geographical variations, risk factors and excess years of life lost
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.07.21264705
DO 10.1101/2021.10.07.21264705
A1 Wai Hoong Chang
A1 Stefanie H. Mueller
A1 Sheng-Chia Chung
A1 Graham R. Foster
A1 Alvina G. Lai
YR 2021
UL http://medrxiv.org/content/early/2021/10/11/2021.10.07.21264705.abstract
AB Background People with liver disease are at increased risk of developing cardiovascular disease (CVD), however, there has yet been an investigation of incidence burden, risk, and premature mortality across a wide range of liver conditions and cardiovascular outcomes.Methods We employed population-wide electronic health records (EHRs; from 1998-2020) consisting of almost 4 million adults to assess regional variations in disease burden of five liver conditions, alcoholic liver disease (ALD), autoimmune liver disease, chronic hepatitis B infection (HBV), chronic hepatitis C infection (HCV) and NAFLD, in England. We analysed regional differences in incidence rates for 17 manifestations of CVD in people with or without liver disease. The associations between biomarkers and comorbidities and risk of CVD in patients with liver disease were estimated using Cox models. For each liver condition, we estimated excess years of life lost (YLL) attributable to CVD (i.e., difference in YLL between people with or without CVD).Results The age-standardised incidence rate for any liver disease was 114.5 per 100,000 person years. The highest incidence was observed in NAFLD (85.5), followed by ALD (24.7), HCV (6.0), HBV (4.1) and autoimmune liver disease (3.7). Regionally, the North West and North East regions consistently exhibited high incidence burden. Age-specific incidence rate analyses revealed that the peak incidence for liver disease of non-viral aetiology is reached in individuals aged 50-59 years. Patients with liver disease had a 2-fold higher incidence burden of CVD (2,634.6 per 100,000 persons) compared to individuals without liver disease (1,339.7 per 100,000 persons). When comparing across liver diseases, atrial fibrillation was the most common initial CVD presentation while hypertrophic cardiomyopathy was the least common. We noted strong positive associations between body mass index and current smoking and risk of CVD. Patients who also had diabetes, hypertension, proteinuric kidney disease, chronic kidney disease, diverticular disease and gastro-oesophageal reflex disorders had a higher risk of CVD, as do patients with low albumin, raised C-reactive protein and raised International Normalized Ratio levels. All types of CVD were associated with shorter life expectancies. When evaluating excess YLLs by age of CVD onset and by liver disease type, differences in YLLs, when comparing across CVD types, were more pronounced at younger ages.Conclusions We developed a public online app (https://lailab.shinyapps.io/cvd_in_liver_disease/) to showcase results interactively. We provide a blueprint that revealed previously underappreciated clinical factors related to the risk of CVD, which differed in the magnitude of effects across liver diseases. We found significant geographical variations in the burden of liver disease and CVD, highlighting the need to devise local solutions. Targeted policies and regional initiatives addressing underserved communities might help improve equity of access to CVD screening and treatment.Competing Interest StatementGRF receives funding from companies that manufacture drugs for hepatitis C virus (AbbVie, Gilead, MSD) and consults for GSK, Arbutus and Shionogi in areas unrelated to this research.Funding StatementAGL is supported by funding from the Wellcome Trust (204841/Z/16/Z), National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre (BRC714/HI/RW/101440), the Academy of Medical Sciences (SBF006\1084), NIHR Great Ormond Street Hospital Biomedical Research Centre (19RX02) and the Health Data Research UK Better Care Catalyst Award (CFC0125). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the Medicines Healthcare Regulatory Authority (UK) Independent Scientific Advisory Committee (21_000363) Clinical Practice Research Datalink (CPRD).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript.AbbreviationsCVDCardiovascular diseaseEHRElectronic health recordsALDAlcoholic liver diseaseHBVChronic hepatitis B infectionHCVChronic hepatitis C infectionNAFLDNon-alcoholic fatty liver diseaseYLLYears of life lostINRInternational Normalised RatioTIATransient ischaemic attackHRHazard ratioCIConfidence intervalALTAlanine aminotransferase